A Study to Evaluate MEDI5752 and Axitinib in Subjects With Advanced Renal Cell Carcinoma (NCT04522323)

🧪 Interventions in This Study

• MEDI5752 (BIOLOGICAL)
• Axitinib (DRUG)
• Lenvatinib (DRUG)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (20 Sites)

• Research Site — Washington D.C., District of Columbia
• Research Site — Fort Myers, Florida
• Research Site — St Louis, Missouri
• Research Site — New York, New York
• Research Site — Cleveland, Ohio
• Research Site — Hershey, Pennsylvania
• Research Site — Nashville, Tennessee
• Research Site — Frankston,
• Research Site — Waratah,
• Research Site — Villejuif,
• Research Site — Barcelona,
• Research Site — Barcelona,
• Research Site — Barcelona,
• Research Site — Barcelona,
• Research Site — Córdoba,
• Research Site — Madrid,
• Research Site — Madrid,
• Research Site — Sabadell,
• Research Site — Seville,
• Research Site — Valencia,

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Advanced Renal Cell Carcinoma

• Testing the Addition of a New Anti-cancer Drug, Radium-223 Dichloride, to the Usual Treatment (Cabozantinib) for Advanced Renal Cell Cancer That Has Spread to the Bone, RadiCaL Study — Birmingham, Alabama
• Trial of Zanzalintinib (XL092) in Combination With Immunotherapy in Patients Who Progress on Adjuvant Therapy in Clear Cell RCC — La Jolla, California
• Sitagliptin With Pembro in RCC and Melanoma — Iowa City, Iowa

Explore by condition: All Advanced Renal Cell Carcinoma clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Review the official NIH record below to find the coordinating site.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.